Zhaoke Ophthalmology Limited (Hong Kong, 06622) filed its Monthly Return for the period ended 31 July 2026, confirming stable capital metrics and ongoing share buy-back activity.

Key Takeaways

1. Share Capital Stable • Authorised capital remained unchanged at 1.60 trillion ordinary shares with a par value of USD 0.00000025 each, equal to USD 0.40 million. • Issued share count stood at 548.75 million shares at both the start and close of July; no new issues or cancellations were completed during the month. • The company held no treasury shares, and its public float continued to exceed the Main Board’s 25 % requirement.

2. Share Repurchases Pending Cancellation • During June and July 2026, the company repurchased a total of 1.72 million shares (1.65 million in June; 66.50 k in July). • All repurchased shares remain outstanding as of 31 July 2026, pending formal cancellation; consequently, they are still included in the 548.75 million issued share figure.

3. Outstanding Share Options • Aggregate outstanding options under four schemes total 41.26 million, equivalent to 7.52 % of the current issued share base. – Pre-IPO scheme: 24.45 million options outstanding. – Post-IPO schemes (three grants): 16.82 million options outstanding combined. • Up to 31.05 million shares could be issued upon exercise of vested options across all schemes. • No options were exercised in July, and the company raised no funds via option conversions.

4. No Convertible Securities or Warrants • The issuer reported no outstanding warrants or convertible instruments and no other equity issuance arrangements in July.

Regulatory Compliance • The board confirmed full compliance with Hong Kong Listing Rules, including public-float requirements and receipt of all monies due from any securities transactions.

Overall, Zhaoke Ophthalmology’s July return highlights a static issued share base, ongoing but as-yet uncancelled buy-backs, and a sizeable but unchanged option overhang, while maintaining full regulatory compliance.